Position: Deputy Director Title: Chief Physician Professional Expertise: Diagnosis and treatment of various thoracic tumors (including lung cancer, thymic tumors, pleural mesothelioma, etc.) Key Social Affiliations: - Member, Multidisciplinary Diagnosis and Treatment Committee on Tumors, Chinese Medical Doctor Association - Member, Non-Small Cell Lung Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO) - Standing Committee Member, Smart Healthcare Expert Committee, Chinese Society of Clinical Oncology (CSCO) - Chair, Tumor Supportive Care Committee, China Association of Geriatric Health - Standing Committee Member, Committee on Difficult Tumors, China Medical Education Association Representative Achievements: Research Project: Study on the mechanism and function of HDGF-mediated CAFs in promoting NSCLC cancer stem cell maintenance during chemotherapy resistance. General Project of the National Natural Science Foundation of China. Publications: 1. Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study. *EBioMedicine*, 2025 Apr;114:105652. doi: 10.1016. Corresponding author. 2. Efficacy and safety of first-line chemoimmunotherapy in young patients with extensive-stage small cell lung cancer: a multicenter retrospective study. *BMC Cancer*, volume 25, Article number: 1136 (2025). Co-corresponding author. 3. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. *Lancet Respir Med*, 2024 Oct;12(10):799-809. Corresponding author. 4. Anlotinib hydrochloride consolidation after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: a truncated, randomized, multicenter, clinical study (ALTER-L029). *Anticancer Drugs*, 2024 Aug 1;35(7):680-685. Corresponding author. 5. First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer. *BMC Cancer*, 2023; 23: 318. Corresponding author. Scientific Awards: 2019 First Prize of the Ministry of Education Science and Technology Progress Award: Establishment and Clinical Application of a Personalized Diagnosis and Treatment System for Lung Cancer Based on Peripheral Blood Molecular Subtyping (Fourth Completer).